MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (NASDAQ: GTXI) today announced that the results from its positive proof of concept Phase 2 clinical trial evaluating enobosarm 9mg in post-menopausal women with estrogen receptor (ER) positive and androgen receptor (AR) positive metastatic breast cancer will be featured in a poster presentation at the San Antonio Breast Cancer Symposium taking place December 9 - 13, 2014, in San Antonio, Texas.
Results from a 22 patient, open-label Phase 2 clinical trial evaluating an oral daily dose of 9mg of enobosarm for the treatment of ER positive and AR positive metastatic breast cancer in women who have previously responded to hormonal therapy for the treatment of their advanced breast cancer, will be presented at a poster session as follows:
Help employers find you! Check out all the jobs and post your resume.
Results from a 22 patient, open-label Phase 2 clinical trial evaluating an oral daily dose of 9mg of enobosarm for the treatment of ER positive and AR positive metastatic breast cancer in women who have previously responded to hormonal therapy for the treatment of their advanced breast cancer, will be presented at a poster session as follows:
Help employers find you! Check out all the jobs and post your resume.
